METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common heart drug boost cancer treatment?
Disease control Recruiting nowThis study tests whether adding propranolol (a beta-blocker used for heart conditions) to standard chemotherapy and immunotherapy can help people with advanced esophageal or stomach cancer that cannot be surgically removed. The drug may reduce stress hormones that can weaken the …
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
New drug combo targets Hard-to-Treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase study tests a combination of two drugs (trastuzumab deruxtecan and azenosertib) in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New combo drug trial hopes to shrink tough cancers
Disease control Recruiting nowThis early-stage study tests a new combination of two drugs (trifluridine/tipiracil and talazoparib) in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side effects. About 45 participants will…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo shows promise for tough stomach cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New immune cocktail targets tough stomach cancers
Disease control Recruiting nowThis study tests a mix of immune cells (agenT-797) and three immunotherapy drugs (botensilimab, balstilimab, ramucirumab) plus chemotherapy (paclitaxel) for people with advanced stomach, esophageal, or gastro-esophageal junction cancer that has worsened after one prior treatment.…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Radiation boosts immune attack on stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are spreading and no longer responding to immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system fight cancer throughout the body. About 28 participants will …
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control Recruiting nowThis early-phase study tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system attack cancer cells, while lenvatinib blocks enzymes tha…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New chemo cocktail aims to extend life in hard-to-treat stomach cancers
Disease control Recruiting nowThis study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunotherapy nivolumab…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:18 UTC